We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Phase 1 Trial of the Mammalian Target of Rapamycin (mTOR) Inhibitor Everolimus Plus Radiation Therapy (RT) for Salvage Treatment of Biochemical Recurrence in Prostate Cancer Patients Following Prostatectomy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01548807
Recruitment Status : Recruiting
First Posted : March 8, 2012
Last Update Posted : September 26, 2016
Information provided by (Responsible Party):
Abramson Cancer Center of the University of Pennsylvania

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Recruiting
  Estimated Primary Completion Date : September 2017
  Study Completion Date : No date given